FluoroPharma, Ground Fluor partner on MFBG agent

By AuntMinnie.com staff writers

June 26, 2018 -- Radiopharmaceutical developer FluoroPharma Medical has acquired an exclusive option to license the meta-fluorobenzylguanidine (MFBG) imaging agent from Ground Fluor Pharmaceuticals.

MFBG, labeled with the isotope F-18, can be used in conjunction with PET for assessing neuronal integrity. It may play an important role in the diagnosis and assessment of various cancers, as well as some aspects of cardiovascular disease, according to the firm.

Ground Fluor Pharmaceuticals established a company-sponsored investigational new drug application and plans to move MFBG into late-stage development in the coming months, with the expectation of U.S. Food and Drug Administration (FDA) approval in 2020. FluoroPharma will work with Ground Fluor to move the agent into routine clinical use.

Copyright © 2018 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking